GLIDE Teaming Profiles
Thank you for showing an interest in ARPA-H’s Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. This page is designed to help facilitate connections between prospective proposers. If either you or your organization are interested in teaming, please submit your information via the portal linked below. Your details will then be added to the list below, which is publicly available.
GLIDE anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are highly encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the GLIDE solicitation.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
Interested in learning more about the GLIDE program?
- Read the GLIDE draft solicitation.
- Register to attend the hybrid Proposers’ Day on October 1, 2024.
- GLIDE program overview page.
Teaming Profiles List
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Contact | Organization Name | Location | Description of Research Focus Area | Description of Teaming Partner | Technical Areas | |
| Nathan Schilaty | University of South Florida | nschilaty@usf.edu | Tampa, FL | Cervical force-based manipulation for improving glymphatic neurovascular flow | Advanced imaging analysis of glymphatic flow and neck vascularity | TA1: Restore Flow Through Physical Interventions |
| Tom Hu | University of Colorado | tom.cc.hu@gmail.com | Aurora, CO | Molecular Imaging | Therapeutics and Diagnostics companies | TA1: Restore Flow Through Physical Interventions |
| Don Tucker | Brain Electrophysiology Laboratory Company | don.tucker@bel.company | Eugene, OR | We provide transcranial electrical stimulation to synchronize the slow oscillations of deep sleep, thereby improving glymphatic clearance of metabolic toxins from the brain. | Collaborators with unique glymphatic function assessment capabilities. | TA1: Restore Flow Through Physical Interventions |
| Stephanie Legere | CCRM | stephanie.legere@ccrm.ca | Toronto, Ontario, Canada | CCRM is a non-profit organization supporting the development & commercialization of cell & gene therapy (CGT) approaches for regenerative medicine. We have a broad network in this space & a strong history of developing CGT technologies, as well as manufacturing capabilities for Phase I/II clinical trials. We are currently interested in understanding how CGT-based modification of the glymphatic system could be used therapeutically for various neurodegenerative diseases or brain injuries. | CCRM collaborates with industry and academic partners around the world to develop new therapies and technologies that can be spun out into companies. We are looking for academic partners that have lab-based capabilities for exploring glymphatic function. We are particularly interested in those with established animal models and methods for assessing glymphatic function in the context of brain injury or neurodegenerative disease. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Abhishek Jain | Texas A&M University | a.jain@tamu.edu | Houston, TX | Our lab contributes new organ-on-chip designs, particularly that include modeling single vessels (blood and lymphatic), vascular networks, hemo- and lympho-dynamics, and integration of these systems into complex tumor and pancreatic microenvironments. We have created a multicellular human lymphangion-chip and a lymphangiogenesis-chip that serves as a disease and drug discovery model to enable preclinical and translational research in lymphedema and rare lymphatic malformations, | We are looking for therapeutic development and clinical trial teams. We are also looking for entrepreneurs who can help with technology translation. | TA1: Restore Flow Through Physical Interventions |
| Kannappan Palaniappan | University of Missouri | palaniappank@missouri.edu | Columbia, MO | University of Missouri-Columbia basic science on the structure-function of lymphatics and blood vasculature in different tissues. | Strengthening therapeutic intervention studies in a clinical setting. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Berk Ozmen | Cleveland Clinic Foundation | ozmenb@ccf.org | Cleveland, OH | Surgical management of lymphedema, artificial intelligence applications in lymphedema microsurgery and supermicrosurgery, robotic surgery for lymphedema | Collaborations in AI and robotics for lymphedema surgery | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| Sameer Sonkusale | Tufts University | sameer@ece.tufts.edu | Medford, MA | Biomedical devices, Flexible Bioelectronics, Examples: Smart bandages, Microneedles, smart sutures, Sensors, Drug Delivery | Expertise in Lymphatic Disorders and treatments | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| John Powderly MD | Carolina BioOncology Institute, PLLC & BioCytics Inc | jpowderly@carolinabiooncology.org | Huntersville, NC | BioCytics Human Applications Lab is developing immune cell therapies derived from the lymphopoietic system, to fight cancer. Specifically, anti-cancer specific subfractions of exhausted-reinvigorated T-cells, gamma-delta T-cells, and naive T-cells educated by dendritic cells and autologous tumor antigens to recapitulate an ex-vivo lymph node. The exhausted-reinvigorated fractions is currently in pre-IND enabling R&D, optimization and beginning GMP upscaling. | Looking for teaming partners that may have synergistic technologies, such as public antigen vaccines, immune modulatory cytokines/agonists, gene editing constructs, and/or manufacturing technology platforms. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Valentina Triacca | Lymphatica Medtech SA | valentina.triacca@lymphatica.ch | Lausanne - Switzerland (US state indicated only to be able to submit the form), AL | Lymphatica Medtech is specialized in research and development of innovative implants for the treatment of lymphatic diseases. Lymphatica's team is interdisciplinary and combines mechanical, electrical, biomedical and software engineering skills with competence in quality, regulatory and clinical strategy. Lymphatica is ready to take on challenges related to the development of medical devices for the treatment of diseases related to body fluid management. | Lymphatica is looking for clinical teams willing to collaborate in the developement of devices by providing clinical inputs, and willing to participate in human factors, usability and clinical studies. | TA1: Restore Flow Through Physical Interventions |
| Donny Hanjaya-Putra | University of Notre Dame | dputra1@nd.edu | Notre Dame, IN | Our lab is working at the forefront of developing transdisciplinary approaches by combining stem cell and bioengineering, biomaterials and microfluidics, as well as lymphatic and systems biology techniques to develop the necessary component in therapeutic lymphangiogenesis. | We are looking for partners with clinically-relevant models for lymphedema to test and commercialize our biomaterials and cell-based therapeutics. | TA1: Restore Flow Through Physical Interventions |
| Anne Taylor | Childrens Hospital of Colorado | anne.taylor@childrenscolorado.org | Denver, CO | We are in the process of building our lymphatic intervention offerings for patients with lymphatic abnormalities following cardiac surgery. We are particularly focused on lymphatic leak in patients with single ventricle heart disease following Stage III palliation with the Fontan procedure. | We would be very interested in exploring new imaging modalities for quick, precise, and accurate diagnostics. While dynamic magnetic resonance lymphangiography has been the gold standard modality, it often requires prolonged anesthesia for congenital heart disease patients. This time under anesthesia is often not well tolerated by patients with single ventricle physiology and other comorbidities. New modalities that do not require anesthesia in our young patients would be impactful. | TA1: Restore Flow Through Physical Interventions |
| Ikbal Sencan-Egilmez | Washington University in St. Louis | ikbal@wustl.edu | St. Louis, MO | Our lab is is focused on elucidating the complex interplay between oxygenation, blood and lymphatic flow, microvascular structure, and metabolism in health and disease. We integrate state-of-the-art in vivo optical microscopy methods, molecular probes, and new experimental approaches for preclinical animal studies in brain and beyond (retina, gut etc.) | experts in lymphatic & glymphatic system disorders and treatments | TA1: Restore Flow Through Physical Interventions |
| Michael Harman | New England Medical Innovation Center | Michael.w.harman@gmail.com | Providence, RI | The New England Medical Innovation Center (NEMIC) is a 501(c)(3) nonprofit located in Rhode Island that provides expert education, connections to funding, and specialized expertise to innovators and entrepreneurs in the medical technologies space. As the region’s premier HealthTech venture hub, we deploy our unique gap analysis approach, draw on an extensive network of subject matter experts, and facilitate clinical access in order to bridge the valley and turn ideas into reality. | NEMIC is primarily seeking partners with biosafety laboratory capabilities to run studies. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Eric Song | Yale University, Rho Bio | eric.song@yale.edu | New Haven, CT | We engineered a potent lymphatic specific agonist that is completely decoupled from unwanted angiogenesis. We aim to bring this molecular therapy to clinic not only to help treat lymphatic based drugs, but also to show that the lymphatic system is an actionable target. | We are looking for partners that can 1.) Provide new delivery methods of our molecule and 2.) provide new models to help us get closer to IND enabling studies. We have strong preclinical data with a recombinant version of the protein that we optimized, but also understand the strengths of other delivery modalities such as mRNA and long lasting polymer/hydrogel formulations. If there are teams that have delivery expertise, we believe we would synergize greatly with them. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Katharina Maisel | University of Maryland | maiselka@umd.edu | College Park, MD | My lab’s research integrates nanotechnology, materials science, and tissue engineering with physiology, medicine, and immunology to probe and target lymphatics using nanoparticles. We have made significant progress in understanding how nanoparticle material properties like surface chemistry, affect their transport across biological barriers including lymphatic vessels. | My lab's research focuses on how to get drugs to the lymphatics, so we are looking to partner with those who have specific therapeutics in mind | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Babak Mehrara | Memorial Sloan Kettering Cancer Center (MSKCC) | katarur@mskcc.org | New York, NY | Our lab investigates breast cancer-related lymphedema, bridging basic science and clinical practice. We use patient samples & animal models to identify and target key inflammatory pathways to improve lymphatic function. We've successfully tested FDA-approved drugs in topical formulations, targeting these pathways in preclinical models. These promising results have paved the way for larger animal studies and eventual human trials, bringing us closer to effective BCRL treatments. | We seek collaborative partnerships for our TA2 application, specifically with academic and industry experts in pharmacology, toxicology studies, drug formulation, and large animal models. Additionally, we are interested in collaborating with TA1 partners specializing in physical and surgical interventions for lymphedema and lymphatic dysfunction, with the aim of submitting a joint application. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy, TA1: Restore Flow Through Physical Interventions |
| Hope O'Donnell | Spring Science | hope@springscience.com | San Carlos, CA | Spring provides advanced AI image analysis tools to researchers across a broad spectrum of applications, using cellular morphology and proteomics to solve complex mechanisms, screen compound libraries, assess clinical biomarkers, develop outcome predictive models, and more. Our expertise in high content imaging, including designing and running assays, ensures robust results across sample types. Custom, web-based AI analysis software simplifies data sharing for multi-institution collaborations. | We are looking for partners who are either interested in screening candidates for TA2 or have a subset of candidates that they would like to further characterize. We can screen or test candidates using AI analysis of cell morphology in cell lines, PBMC, or other primary cells in vitro, or work with other teams to analyze images and other data generated in more complex model systems. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Kazuhide Shaun Okuda | La Trobe University | k.okuda@latrobe.edu.au | Melbourne, Australia | My research program's focus is on identifying mechanisms and therapeutic leads to enhance lymphangiogenesis using the unique zebrafish model. I have access to and is establishing novel zebrafish lymphoedema models that can be used to test these hypothesis. | Researchers interested in utilising the zebrafish model (live-imaging, high throughput drug discovery, disease modelling) to accelerate in vivo discovery of lymphoedema therapeutics and targets. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Huiliang Wang | University of Texas at Austin | evanwang@utexas.edu | Austin, TX | Non-viral DNA/mRNA delivery, Sono-optogenetics, Ultrasound Neuromodulation | expertise in lymphatic & glymphatic system | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy, TA1: Restore Flow Through Physical Interventions |
| Michelle Farrington | AFFOA | mfarrington@affoa.org | Cambridge, MA | National Manufacturing Institute with a focus on advanced textile technologies. Research area focus includes advanced sensing and actuation technology integrated into textile form factors. 3D and circular knitting, weaving and embroidery available at our facility along with electronics and soft system integration and product design. We also have 150 member network from the domestic supply chain ready to bring a domestic supply chain to those working to accelerate a product's time to market. | Clinical expertise in lymphatic disorders and compression based interventions. | TA1: Restore Flow Through Physical Interventions |
| Lydia Gushgari | SPOC Proteomics | lydiag@spoc.bio | Scottsdale, AZ | SPOC Proteomics developed a novel protein-biosensor platform for simultaneous kinetic (affinity) screening of 1000 proteins or antibody-based therapeutic candidates on a single chip, at 1/10th the cost compared to current recombinant protein workflows. SPOC biosensors support high-throughput pre-clinical drug discovery, wet lab testing of AI-designed drugs, affinity ranking, lead candidate selection, and data generation to train AI/ML models. SPOC protein biosensor chips are customizable. | SPOC Proteomics is interested in partnering with TA2 proposers to support high-throughput drug discovery through kinetic screening, generating data to train AI models, epitope mapping/binning, off-target screening, to enable down selection of antibody-based drugs/biologics, CARs, PROTACs, and/or small molecules. We are looking for partners with specific disease expertise, AI-enabled drug developers, with the expertise to conduct the preclinical and clinical studies required by the program. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Theodore Alexandrov | University of California San Diego | talexandrov@health.ucsd.edu | San Diego, CA | We have developed a method for single-cell metabolomics of lymphocytes. The method provides comprehensive metabolic profiles for single lymphocytes isolated from blood and reflects the metabolic and functional states of immune cells and their heterogeneity. It can be used to infer the metabolic mode of action of drugs or therapies as well as help understanding metabolic reprogramming of lymphocytes or CAR-T cells in diagnostics, therapy development and response monitoring. | We are looking for clinical partners to make translational impact with our technologies as well as for methodological collaborators to jointly develop better technologies for these aims, in particular in the single-cell analysis space | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Robin Smith | Wonderlab Bio | robin@wonderlab.bio | Boston, MA | Our organization has allogenic cell lines for use in cell therapies that match 90% of the US population. These lines are available for teaming or partnership for manufacturing and research and development. | We would like to team with organization to supply necessary allogeneic cell lines derived from iPS cells for the purposes of this program. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| David Nelles | Tacit Therapeutics, Inc. | dnelles@tacittx.com | San Francisco, CA | Tacit Therapeutics has created a RNA repair technology that supports the repair of multiple kilobases of specific RNAs. We propose improving lymphatic function by altering expression of specific genes using our proprietary RNA trans-splicing process to repair mutations and introducing beneficial variants | We are interested in teaming up with organizations that have validated gene delivery vectors that can target lymphatic tissues | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Michael Paukshto | Fibralign Corp | mpaukshto@fibralignbio.com | Union City, CA | Fibralign’s novel devices direct and promote lymphatic vessel regeneration that has been demonstrated in multiple preclinical and clinical studies. First product, BioBridge®, has been used successfully in over 350 surgeries for treatment of lymphedema with no complications or adverse events related to the device. Next generation of BioBridge device will target neurological disorders where the impaired meningeal and/or deep cervical lymphatics reduce CSF drainage and diminish immune function. | Expert in anatomy of meningeal and cervical lymphatics; quantitative evaluation of CSF drainage to the cervical lymph nodes (human, animal model); contrast enhanced high frequency ultrasound for mapping deep cervical lymphatics (human, animal model). | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Melissa Aldrich | UTHealth | Melissa.B.Aldrich@uth.tmc.edu | Houston, TX | Lymphedema secondary to cancer treatment, lymphedema associated with Turner Syndrome. Understanding molecular and cellular mechanisms driving development and maintenance of secondary lymphedema | Vaccine development and production | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Amina Qutub | UTSA | amina.qutub@utsa.edu | San Antonio, TX | Our UTSA - UT Health team develops experimental-computational frameworks to rapidly screen therapies for rare and common diseases. This includes AI screens and metabolic imaging modalities to assess functional restoration in capillaries and lymphatics. | Lymphatic disease communities and patients, biotechs developing non-invasive imaging devices | TA1: Restore Flow Through Physical Interventions |
| charles kim | Mass General Hospital Cancer Center, NewCo | charleskimck@outlook.com | Boston, MA | Our objective is to deliver a functional cure for all cases of lymphoma - regardless of acquired somatic mutations or tissue of origin - by drugging mechanisms of cellular plasticity vital to malignant progression. To accomplish this, we will pioneer the development of first-in-class chemical 'magnets' capable of reprogramming the phenotype of cancerous lymphatic cells, transforming them into benign cell states that demonstrate pro-apoptotic, non-metastatic physiology. | We are looking for collaborative partners who are (1) building AI/machine learning algorithms that accelerate hit-to-lead optimization, characterize epigenetic cell states during drug treatment, identify relevant clinical biomarkers for each lymphoma subclass, (2) developing small molecule therapeutic delivery technologies targeting the lymphatic system and (3) developing imaging capabilities of the lymphatic system in preclinical disease models. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Susan Thomas | Georgia Institute of Technology | susan.thomas@gatech.edu | Atlanta, GA | therapeutic delivery to lymphatic system, lymphatic targeting drug delivery technology, lymphedema, immunotherapy, lymphatic function modulators, combination therapy, sustained release technologies | clinical partners, chemical biologists, medicinal chemists, interventional radiologists, lymphatic biologists, pharmaceutical scientists, industry partners | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Natalie Trevaskis | Monash University | natalie.trevaskis@monash.edu | Melbourne, HI | Our team has extensive expertise in therapeutic delivery to the lymphatic system, including administration of novel systems via various routes to target tissue-specific lymphatics | We would be interested to partner with other teams that have therapeutic molecules that can benefit from targeted delivery to the lymphatics | TA1: Restore Flow Through Physical Interventions |
| James Moore | Imperial College London | james.moore.jr@imperial.ac.uk | London, UM | Developing an implantable device to be deployed during cancer surgery to re-establish lymphatic vessels and prevent lymphedema. The device is capable of gradual release of lymphangiogenic factors. | Those developing lymphangiogenic biopharma products that could benefit from localized gradual release. | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| Greg King | Fibralign Corp | gking@fibralignbio.com | Union City, CA | Fibralign is a startup dedicated to the development of therapeutic devices for repairing and restoring lymphatic function based on a novel bioengineered nanofibrillar collagen scaffolding technology, which has been shown to promote and direct lymphangiogenesis. Research areas are focused on addressing lymphedema, neurological disorders and other lymphatic-related diseases, and advancing the development of an injectable scaffolding platform and combination devices for localized drug delivery. | Researchers, clinicians, and surgeons focused on addressing lymphatic disorders and developing innovative treatments. Neurologists, clinicians, surgeons, and researchers working on further understanding the role the lymphatic system has in neurological disorders, with translational focus on therapeutic treatments, diagnostic imaging, and biomarkers. Organizations working on pharmacologic, gene, and cell therapies for lymphatic repair, with interest in a novel localized delivery device. | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| Vrad Levering | Triple Ring Technologies | vlevering@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products across medtech, life sciences, and sustainability. Our interdisciplinary team, including many PhDs, excels in advancing technologies up the TRL scale and collaborating with academic researchers. We have a strong track record of engaging with ARPA-H, both as subcontractors and primary awardees. We offer services from basic tech development to prototype design and manufacturing. Fully ISO 13485 certified. | TRT partners with innovators to solve tough problems, launch breakthrough products, and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, and complex system integration. We welcome teaming partners with medical or specific domain expertise, and encourage bold ideas beyond current limits. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Benjamin Levi | University of Texas Southwestern | Benjamin.levi@UTSouthwestern.edu | Dallas, TX | Our research team has expertise and interest on the role of lymphatics on musculoskeletal injury, repair and regeneration. Specifically, we focus on understanding the role and interaction of lymphatics with local progenitor cells and myeloid cells to guide tissue repair, fibrosis and regeneration. We have expertise in models of muscle, tendon and bone injury and regeneration. Technically we have expertise in lineage tracing, single cell and spatial transcriptomics and metabolomics. | Our team is looking for partners in drug delivery platforms and imaging to assess lymphatic function. While we have shown lymphatic regeneration after musculoskeletal injury, having a partner with expertise on the function of these new lymphatics would help advance the science. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Joseph Wu | Stanford University School of Medicine | joewu@stanford.edu | Stanford, CA | drug discovery | synergistic partnership | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Brent Dixon | BioCytics | BDIXON@biocytics.com | Huntersville, NC | BioCytics, Inc., founded in 2005, has a focused mission to directly apply living cells in clinical trials as affordable individualized immune cellular therapies manufactured at the Point of Care (PoC). Expertise and services include clinical trials, research and development, GMP manufacturing, immunology, CLIA Lab assays, and biobanking/clinically annotated biospecimens. | Those looking for R&D laboratory services, proliferation assays, clinical development, prototype validation, GMP manufacturing of immune cells, and/or study design and clinical trials. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| June Wu | Columbia University | jw92@cumc.columbia.edu | New York, NY | We are broadly interested in basic and translational research in Vascular Anomalies. We have particular interest in slow-flow vascular malforations, including lymphatic malformations (LMs) and complex lymphatic anomalies (CLAs). We have focused on how genetic variants affect therapeutic response, as well as how genetic variants in LMs and CLAs affect biological behavior of diseased tissues. | We are looking for other Vascular Anomalies Centers as potential partners for multi-center clinical trials. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Michelle Lampa | Pasqal | michelle.lampa@pasqal.com | Boston, MA | We are a globally recognized neutral atom-based, analog quantum computing company creating enterprise-grade devices. As data sets become more complex, we strongly believe that quantum computing is needed to accelerate the groundbreaking work in the industries that affect our everyday lives, especially in the life sciences. | We are looking for entities who are working with complex data sets, e.g. drug discovery, optimization, among others. We can be the hardware provider and the partner that works with these potential teaming partners to identify the quantum algorithm that would provide the best outcomes. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Yonatan Lipsitz | Lilium Therapeutics | yonatan@liliumtx.com | Cambridge, MA | Targeted in vivo gene therapy and synthetic biology | Novel relevant targets and genetic payloads | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| nick hughes | Acrobat Genomics | nick.hughes@acrobatgenomics.com | San Carlos, CA | Acrobat Genomics has developed a novel high-throughput method that leverages advancements in computational methods, synthetic biology, and genomics in order to develop next-generation gene editing tools for therapeutic applications. | We are technology experts and are looking for partners that have expertise in lymphatics biology. We have preliminary therapeutic hypotheses that are well-suited to the unique features of our technology that we would like to refine with a partner. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Laura Powell | EverGlade Consulting | lpowell@everglade.com | Houston, TX | EverGlade Consulting helps companies secure and manage non-dilutive federal funding. We offer services ranging from proposal writing support through post-award program management and implementation of systems to comply with federal regulations. We have helped companies win ARPA-H awards through the successful preparation of solution summaries and full proposals. | EverGlade Consulting is available to assist partners in the preparation of solution summaries and full proposals to ARPA-H. We can also assist with negotiations and post-award contract administration, including program management support, preparation of contract deliverables, and invoicing. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Lee JunHeon | KoreaCancerRehabilitationExerciseInstitute | zhzh0515@naver.com | Seoul | In the rehabilitation of lymphedema patients, we develop and study other forms of physical therapy approaches in addition to the existing MLD method or compression bandage, and educate Korean physical therapists about complex lymphatic physical therapy. | Study and research on various forms of surgical or physical interventions. | TA1: Restore Flow Through Physical Interventions |